Bracco Diagnostics Inc.
107 College Road East
44 articles with Bracco Diagnostics Inc.
Bracco Diagnostics Inc. Receives U.S. FDA Approval for VARIBAR® THIN LIQUID (barium sulfate) for oral suspension
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, today announced the Food and Drug FDA approval for VARIBAR® THIN LIQUID (barium sulfate) for oral suspension which is indicated for modified barium swallow (MBS) studies used to detect and assess the type and severity of swallowing disorders also known as dysphagia.
Bracco Diagnostics Inc. Launches Initiative to Empower the Growth of Magnetic Resonance (MR) Practices
Customizable Media Kit for ProHance® (Gadoteridol) Injection, 279.3 mg/mL Customers to Drive Referrals and Improve Patient Satisfaction
New study of ultrasound enhancing agents in echocardiography reaffirms safety profile of LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business, shares the results of a new prospective clinical study of the use of ultrasound enhancing agents (UEAs) in transthoracic echocardiography reaffirming the proven safety profile of its LUMASON ultrasound enhancing agent.
As the Clinical Evidence Evolves, the Website Provides an Updated Look at the Latest Peer-Reviewed Data
Bracco Diagnostics Inc. Acknowledges Speech Language Pathologists during June - National Dysphagia Awareness Month
June is designated Dysphagia Awareness Month by the National Foundation of Swallowing Disorders.
Bracco Diagnostics Inc. Showcases its Portfolio of Products and Solution Innovations to Improve Patient Care at the 2018 Radiological Society of North America (RSNA) Annual Meeting
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, reaffirms the company's vision on addressing the diagnostic imaging needs of today and tomorrow.
1/30/2018The approval was based on data specifically obtained in pediatric patients younger than 2 years of age.
Bracco Diagnostics Announces The Launch Of The PROTOCO2L TOUCH Colon Insufflator For Use In CT Colonography Procedures
Bracco Diagnostics Receives U.S. FDA Approval For VARIBAR PUDDING (Barium Sulfate) Oral Paste For Fluoroscopy
Bracco Diagnostics Release: Company's LUMASON (Sulfur Hexafluoride Lipid-Type A Microspheres) For Injectable Suspension, For Intravenous Use Or Intravesical Use, Receives U.S. Food And Drug Administration Approval For Use In Ultrasonography Of The Urinary
Bracco Diagnostics Release: The FDA Removes The Contraindication For Use Of Diagnostic Company's LUMASON (Sulfur Hexafluoride Lipid-Type A Microspheres) For Injectable Suspension, For Intravenous Use Or Intravesical Use, In Patients With Cardiac Shunts
Bracco Diagnostics's CT Exprès 3D Contrast Media Delivery System Is The First And Only Syringe-Less Computed Tomography (CT) Power Injector Available In The U.S.
Bracco Diagnostics Release: Importance Of Myocardial Perfusion Positron Emission Tomography Recognized In New Joint Position Statement By The American Society of Nuclear Cardiology And The Society Of Nuclear Medicine And Molecular Imaging
Bracco Diagnostics Release: Virtual Colonoscopy Receives Highest Grade In The New U.S. Preventive Services Task Force Recommendation For Colorectal Cancer Screening
Bracco Diagnostics Receives Innovative Technology Designation From Vizient For LUMASON (Sulfur Hexafluoride Lipid-Type A Microspheres) For Injectable Suspension For Contrast Echocardiography
Bracco Diagnostics Grabs First Approval by the FDA for Contrast Enhanced Ultrasonography of the Liver for LUMASON
Bracco Diagnostics Receives Second U.S. FDA Approval For Barium-Based Products, The First In Computed Tomography